Native state kinetic stabilization as a strategy to ameliorate protein misfolding diseases: A focus on the transthyretin amyloidoses

Accounts of Chemical Research

Volumn 38, Issue 12, 2005, Pages 911-921

  Johnson, Steven M ^a   Wiseman, R Luke ^a,c   Sekijima, Yoshiki ^a   Green, Nora S ^a,b   Adamski Werner, Sara L ^a,d   Kelly, Jeffery W ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b RANDOLPH MACON COLLEGE   (United States)

^c NEW YORK UNIVERSITY   (United States)

^d Senomix Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PREALBUMIN; THYROXINE;

AMYLOIDOSIS; BINDING SITE; CHEMISTRY; DRUG DESIGN; GENETICS; HUMAN; KINETICS; METABOLISM; PROTEIN CONFORMATION; PROTEIN FOLDING; REVIEW; STRUCTURE ACTIVITY RELATION;

AMYLOIDOSIS; BINDING SITES; DRUG DESIGN; HUMANS; KINETICS; PREALBUMIN; PROTEIN CONFORMATION; PROTEIN FOLDING; STRUCTURE-ACTIVITY RELATIONSHIP; THYROXINE;

EID: 28244502156     PISSN: 00014842     EISSN: None     Source Type: Journal    
DOI: 10.1021/ar020073i     Document Type: Review

References (72)

1. Dobson, C. M. Protein folding and misfolding. Nature 2003, 426, 884-890.
2. Selkoe, D. J. Folding proteins in fatal ways. Nature 2003, 426, 900-904.
3. De Lorenzi, E.; Giorgetti, S.; Grossi, S.; Merlini, G.; Caccialanza, G.; Bellotti, V. Pharmaceutical strategies against amyloidosis: old and new drugs in targeting a "protein misfolding disease". Curr. Med. Chem. 2004, 11, 1065-1084.
4. Colon, W.; Kelly, J. W. Partial denaturation of transthyretin is sufficient for amyloid fibril formation in vitro. Biochemistry 1992, 31, 8654-8660.
5. Lai, Z.; Colon, W.; Kelly, J. W. The acid-mediated denaturation pathway of transthyretin yields a conformational intermediate that can self-assemble into amyloid. Biochemistry 1996, 35, 6470-6482.
6. Lashuel, H. A.; Lai, Z.; Kelly, J. W. Characterization of the transthyretin acid denaturation pathways by analytical ultracentrifugation: implications for wild-type, V30M, and L55P amyloid fibril formation. Biochemistry 1998, 37, 17851-17864.
7. Liu, K.; Cho, H. S.; Lashuel, H. A.; Kelly, J. W.; Wemmer, D. E. A glimpse of a possible amyloidogenic intermediate of transthyretin. Nat. Struct. Biol. 2000, 7, 754-757.
8. Jiang, X.; Smith, C. S.; Petrassi, H. M.; Hammarstrom, P.; White, J. T.; Sacchettini, J. C.; Kelly, J. W. An engineered transthyretin monomer that is nonamyloidogenic, unless it is partially denatured. Biochemistry 2001, 40, 11442-11452.
9. Kelly, J. W.; Colon, W.; Lai, Z.; Lashuel, H. A.; McCulloch, J.; McCutchen, S. L.; Miroy, G. J.; Peterson, S. A. Transthyretin quaternary and tertiary structural changes facilitate misassembly into amyloid. Adv. Protein Chem. 1997, 50, 161-181.
10. Guijarro, J. I.; Sunde, M.; Jones, J. A.; Campbell, I. D.; Dobson, C. M. Amyloid fibril formation by an SH3 domain. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 4224-4228.
11. McParland, V. J.; Kad, N. M.; Kalverda, A. P.; Brown, A.; Kirwin-Jones, P.; Hunter, M. G.; Sunde, M.; Radford, S. E. Partially unfolded states of beta(2)-microglobulin and amyloid formation in vitro. Biochemistry 2000, 39, 8735-8746.
12. Dumoulin, M.; Last, A. M.; Desmyter, A.; Decanniere, K.; Canet, D.; Larsson, G.; Spencer, A.; Archer, D. B.; Sasse, J.; Muyldermans, S.; Wyns, L.; Redfield, C.; Matagne, A.; Robinson, C. V.; Dobson, C. M. A camelid antibody fragment inhibits the formation of amyloid fibrils by human lysozyme. Nature 2003, 424, 783-788.
13. Hammarstrom, P.; Schneider, F.; Kelly, J. W. Trans-suppression of misfolding in an amyloid disease. Science 2001, 293, 2459-2462.
14. Hammarstrom, P.; Wiseman, R. L.; Powers, E. T.; Kelly, J. W. Prevention of transthyretin amyloid disease by changing protein misfolding energetics. Science 2003, 299, 713-716.
15. Cohen, F. E.; Kelly, J. W. Therapeutic approaches to protein-misfolding diseases. Nature 2003, 426, 905-909.
16. Buxbaum, J. N.; Tagoe, C. E. The genetics of the amyloidoses. Annu. Rev. Med. 2000, 51, 543-569.
17. Westermark, P.; Sletten, K.; Johansson, B.; Cornwell, G. G., 3rd. Fibril in senile systemic amyloidosis is derived from normal transthyretin. Proc. Natl. Acad. Sci. U.S.A. 1990, 87, 2843-2845.
18. Ikeda, S.; Nakazato, M.; Ando, Y.; Sobue, G. Familial transthyretin-type amyloid polyneuropathy in Japan: clinical and genetic heterogeneity. Neurology 2002, 58, 1001-1007.
19. Sousa, A.; Coelho, T.; Barros, J.; Sequeiros, J. Genetic epidemiology of familial amyloidotic polyneuropathy (FAP)-type I in Povoa do Varzim and Vila do Conde (north of Portugal). Am. J. Med. Genet. 1995, 60, 512-521.
20. Jiang, X.; Buxbaum, J. N.; Kelly, J. W. The V122I cardiomyopathy variant of transthyretin increases the velocity of rate-limiting tetramer dissociation, resulting in accelerated amyloidosis. Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 14943-14948.
21. McCutchen, S. L.; Lai, Z.; Miroy, G. J.; Kelly, J. W.; Colon, W. Comparison of lethal and nonlethal transthyretin variants and their relationship to amyloid disease. Biochemistry 1995, 34, 13527-13536.
22. Jacobson, D. R.; Pastore, R. D.; Yaghoubian, R.; Kane, I.; Gallo, G.; Buck, F. S.; Buxbaum, J. N. Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans. N. Engl. J. Med. 1997, 336, 466-473.
23. Gambetti, P.; Russo, C. Human brain amyloidoses. Nephrol. Dial. Transplant 1998, 13(Suppl. 7), 33-40.
24. Sekijima, Y.; Hammarstrom, P.; Matsumura, M.; Shimizu, Y.; Iwata, M.; Tokuda, T.; Ikeda, S.; Kelly, J. W. Energetic characteristics of the new transthyretin variant A25T may explain its atypical central nervous system pathology. Lab. Invest. 2003, 83, 409-417.
25. Hammarstrom, P.; Sekijima, Y.; White, J. T.; Wiseman, R. L.; Lim, A.; Costello, C. E.; Altland, K.; Garzuly, F.; Budka, H.; Kelly, J. W. D18G transthyretin is monomeric, aggregation prone, and not detectable in plasma and cerebrospinal fluid: a prescription for central nervous system amyloidosis? Biochemistry 2003, 42, 6656-6663.
26. Miller, S. R.; Sekijima, Y.; Kelly, J. W. Native state stabilization by NSAIDs inhibits transthyretin amyloidogenesis from the most common familial disease variants. Lab. Invest. 2004, 84, 545-552.
27. Reixach, N.; Deechongkit, S.; Jiang, X.; Kelly, J. W.; Buxbaum, J. N. Tissue damage in the amyloidoses: Transthyretin monomers and nonnative oligomers are the major cytotoxic species in tissue culture. Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 2817-2822.
28. Sekijima, Y.; Wiseman, R. L.; Matteson, J.; Hammarstrom, P.; Miller, S. R.; Sawkar, A. R.; Balch, W. E.; Kelly, J. W. The Biological and Chemical Basis for Tissue Selective Amyloid Disease. Cell 2005, 121, 73-85.
29. Blake, C. C.; Geisow, M. J.; Oatley, S. J.; Rerat, B.; Rerat, C. Structure of prealbumin: secondary, tertiary and quaternary interactions determined by Fourier refinement at 1.8 Å. J. Mol. Biol. 1978, 121, 339-356.
30. Hornberg, A.; Eneqvist, T.; Olofsson, A.; Lundgren, E.; Sauer-Eriksson, A. E. A comparative analysis of 23 structures of the amyloidogenic protein transthyretin. J. Mol. Biol. 2000, 302, 649-669.
31. Stockigt, J. R. In Endocrinology, 4th ed.; Degroot, L. J., Jameson, J. L., Eds.; W. B. Saunders Co.: Philadelphia, PA, 2001; pp 1314-1326.
32. Hamilton, J. A.; Benson, M. D. Transthyretin: a review from a structural perspective. Cell. Mol. Life Sci. 2001, 58, 1491-1521.
33. Klabunde, T.; Petrassi, H. M.; Oza, V. B.; Raman, P.; Kelly, J. W.; Sacchettini, J. C. Rational design of potent human transthyretin amyloid disease inhibitors. Nat. Struct. Biol. 2000, 7, 312-321.
34. Hurshman, A. R.; White, J. T.; Powers, E. T.; Kelly, J. W. Transthyretin aggregation under partially denaturing conditions is a downhill polymerization. Biochemistry 2004, 43, 7365-7381.
35. Hammarstrom, P.; Jiang, X.; Hurshman, A. R.; Powers, E. T.; Kelly, J. W. Sequence-dependent denaturation energetics: A major determinant in amyloid disease diversity. Proc. Natl. Acad. Sci. U.S.A. 2002, 99 (Suppl 4), 16427-16432.
36. Holmgren, G.; Ericzon, B. G.; Groth, C. G.; Steen, L.; Suhr, O.; Andersen, O.; Wallin, B. G.; Seymour, A.; Richardson, S.; Hawkins, P. N. Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis. Lancet 1993, 341, 1113-1116.
37. Tan, S. Y.; Pepys, M. B.; Hawkins, P. N. Treatment of amyloidosis. Am. J. Kidney Dis. 1995, 26, 267-285.
38. Suhr, O. B.; Herlenius, G.; Friman, S.; Ericzon, B. G. Liver transplantation for hereditary transthyretin amyloidosis. Liver Transplant. 2000, 6, 263-276.
39. Olofsson, B. O.; Backman, C.; Karp, K.; Suhr, O. B. Progression of cardiomyopathy after liver transplantation in patients with familial amyloidotic polyneuropathy, Portuguese type. Transplantation 2002, 73, 745-751.
40. Coelho, T.; Carvalho, M.; Saraiva, M. J.; Alves, I.; Almeida, M. R.; Costa, P. P. A strikingly benign evolution of FAP in an individual found to be a compound heterozygote for two TTR mutations: TTR Met 30 and TTR Met 119. J. Rheumatol. 1993, 20, 179.
41. (41 ) Coelho, T.; Chorao, R.; Sausa, A.; Alves, I.; Torres, M. F.; Saraiva, M. J. Compound heterozygotes of transthyretin Met30 and transthyretin Met119 are protected from the devastating effects of familial amyloid polyneuropathy. Neuromuscular Disord. 1996, 6, 27.
42. Schneider, F.; Hammarstrom, P.; Kelly, J. W. Transthyretin slowly exchanges subunits under physiological conditions: A convenient chromatographic method to study subunit exchange in oligomeric proteins. Protein Sci. 2001, 10, 1606-1613.
43. Sebastiao, M. P.; Lamzin, V.; Saraiva, M. J.; Damas, A. M. Transthyretin stability as a key factor in amyloidogenesis: X-ray analysis at atomic resolution. J. Mol. Biol. 2001, 306, 733-744.
44. Foss, T. R.; Kelker, M. S.; Wiseman, R. L.; Wilson, I. A.; Kelly, J. W. Kinetic stabilization of the native state by protein engineering: Implications for inhibition of transthyretin amyloidogenesis. J. Mol. Biol. 2005, 347, 841-854.
45. Hammarstrom, P.; Jiang, X.; Deechongkit, S.; Kelly, J. W. Anion shielding of electrostatic repulsions in transthyretin modulates stability and amyloidosis: insight into the chaotrope unfolding dichotomy. Biochemistry 2001, 40, 11453-11459.
46. Zhang, Q.; Kelly, J. W. Cys10 mixed disulfides make transthyretin more amyloidogenic under mildly acidic conditions. Biochemistry 2003, 42, 8756-8761.
47. Zhang, Q.; Kelly, J. W. Cys-10 Mixed Disulfide Modifications Exacerbate Transthyretin Familial Variant Amyloidogenicity: A Likely Explanation for Variable Clinical Expression of Amyloidosis and the Lack of Pathology in C10S/V30M Transgenic Mice? Biochemistry 2005, 44, 9079-9085.
48. Wiseman, R. L.; Johnson, S. M.; Kelker, M. S.; Foss, T.; Wilson, I. A.; Kelly, J. W. Kinetic Stabilization of an Oligomeric Protein by a Single Ligand Binding Event. J. Am. Chem. Soc. 2005, 127, 5540-5551.
49. Neumann, P.; Cody, V.; Wojtczak, A. Structural basis of negative cooperativity in transthyretin. Acta Biochim. Pol. 2001, 48, 867-875.
50. Miroy, G. J.; Lai, Z.; Lashuel, H. A.; Peterson, S. A.; Strang, C.; Kelly, J. W. Inhibiting transthyretin amyloid fibril formation via protein stabilization. Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 15051-15056.
51. Oza, V. B.; Petrassi, H. M.; Purkey, H. E.; Kelly, J. W. Synthesis and evaluation of anthranilic acid-based transthyretin amyloid fibril inhibitors. Bioorg. Med. Chem. Lett. 1999, 9, 1-6.
52. Oza, V. B.; Smith, C.; Raman, P.; Koepf, E. K.; Lashuel, H. A.; Petrassi, H. M.; Chiang, K. P.; Powers, E. T.; Sachettinni, J.; Kelly, J. W. Synthesis, structure, and activity of diclofenac analogues as transthyretin amyloid fibril formation inhibitors. J. Med. Chem. 2002, 45, 321-332.
53. Baures, P. W.; Peterson, S. A.; Kelly, J. W. Discovering transthyretin amyloid fibril inhibitors by limited screening. Bioorg. Med. Chem. 1998, 6, 1389-1401.
54. Baures, P. W.; Oza, V. B.; Peterson, S. A.; Kelly, J. W. Synthesis and evaluation of inhibitors of transthyretin amyloid formation based on the nonsteroidal antiinflammatory drug, flufenamic acid. Bioorg. Med. Chem. 1999, 7, 1339-1347.
55. Peterson, S. A.; Klabunde, T.; Lashuel, H. A.; Purkey, H.; Sacchettini, J. C.; Kelly, J. W. Inhibiting transthyretin conformational changes that lead to amyloid fibril formation. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 12956-12960.
56. Adamski-Werner, S. L.; Palaninathan, S. K.; Sacchettini, J. C.; Kelly, J. W. Diflunisal analogues stabilize the native state of transthyretin. Potent inhibition of amyloidogenesis. J. Med. Chem. 2004, 47, 355-374.
57. Purkey, H. E.; Palaninathan, S. K.; Kent, K. C.; Smith, C.; Safe, S. H.; Sacchettini, J. C.; Kelly, J. W. Hydroxylated polychlorinated biphenyls selectively bind transthyretin in blood and inhibit amyloidogenesis: rationalizing rodent PCB toxicity. Chem. Biol. 2004, 11, 1719-1728.
58. Razavi, H.; Powers, E. T.; Purkey, H. E.; Adamski-Werner, S. L.; Chiang, K. P.; Dendle, M. T.; Kelly, J. W. Design, synthesis, and evaluation of oxazole transthyretin amyloidogenesis inhibitors. Bioorg. Med. Chem. Lett. 2005, 15, 1075-1078.
59. Razavi, H.; Palaninathan, S. K.; Powers, E. T.; Wiseman, R. L.; Purkey, H. E.; Mohamedmohaideen, N. N.; Deechongkit, S.; Chiang, K. P.; Dendle, M. T.; Sacchettini, J. C.; Kelly, J. W. Benzoxazoles as transthyretin amyloid fibril inhibitors: synthesis, evaluation, and mechanism of action. Angew. Chem., Int. Ed. 2003, 42, 2758-2761.
60. Petrassi, H. M.; Klabunde, T.; Sacchettini, J. C.; Kelly, J. W. Structure-Based Design of N-Phenyl Phenoxazine Transthyretin Amyloid Fibril Inhibitors. J. Am. Chem. Soc. 2000, 122, 2178-2192.
61. Petrassi, H. M.; Johnson, S. M.; Purkey, H.; Chiang, K. P.; Walkup, T.; Jiang, X.; Powers, E. T.; Kelly, J. W. Potent and Selective Structure-Based Dibenzofuran Inhibitors of Transthyretin Amyloidogenesis: Kinetic Stabilization of the Native State. J. Am. Chem. Soc. 2005, 127, 6662-6671.
62. Johnson, S. M.; Petrassi, H. M.; Palaninathan, S. K.; Mohamedmohaideen, N. N.; Purkey, H.; Nichols, C.; Chiang, K. P.; Walkup, T.; Sacchettini, J. C.; Sharpless, K. B.; Kelly, J. W. Bisaryloxime Ethers as Potent Inhibitors of Transthyretin Amyloid Fibril Formation. J. Med. Chem. 2005, 48, 1576-1587.
63. Sacchettini, J. C.; Kelly, J. W. Therapeutic strategies for human amyloid diseases. Nat. Rev. Drug Discovery 2002, 1, 267-275.
64. McCammon, M. G.; Scott, D. J.; Keetch, C. A.; Greene, L. H.; Purkey, H. E.; Petrassi, H. M.; Kelly, J. W.; Robinson, C. V. Screening transthyretin amyloid fibril inhibitors: characterization of novel multiprotein, multiligand complexes by mass spectrometry. Structure 2002, 10, 851-863.
65. Sousa, M. M.; Cardoso, I.; Fernandes, R.; Guimaraes, A.; Saraiva, M. J. Deposition of transthyretin in early stages of familial amyloidotic polyneuropathy: evidence for toxicity of nonfibrillar aggregates. Am. J. Pathol. 2001, 159, 1993-2000.
66. Wiseman, R. L.; Green, N. S.; Kelly, J. W. Kinetic Stabilization of an Oligomeric Protein under Physiological Conditions Demonstrated by a Lack of Subunit Exchange: Implications for Transthyretin Amyloidosis. Biochemistry 2005, 44, 9265-9274.
67. Green, N. S.; Palaninathan, S. K.; Sacchettini, J. C.; Kelly, J. W. Synthesis and characterization of potent bivalent amyloidosis inhibitors that bind prior to transthyretin tetramerization. J. Am. Chem. Soc. 2003, 125, 13404-13414.
68. Purkey, H. E.; Dorrell, M. I.; Kelly, J. W. Evaluating the binding selectivity of transthyretin amyloid fibril inhibitors in blood plasma. Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 5566-5571.
69. Ray, S. S.; Nowak, R. J.; Brown, R. H., Jr.; Lansbury, P. T., Jr. Small-molecule-mediated stabilization of familial amyotrophic lateral sclerosis-linked superoxide dismutase mutants against unfolding and aggregation. Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 3639-3644.
70. Bernier, V.; Lagace, M.; Bichet, D. G.; Bouvier, M. Pharmacological chaperones: potential treatment for conformational diseases. Trends Endocrinol. Metab. 2004, 15, 222-228.
71. Fan, J. Q. A contradictory treatment for lysosomal storage disorders: inhibitors enhance mutant enzyme activity. Trends Pharmacol. Sci. 2003, 24, 355-360.
72. Sawkar, A. R.; Cheng, W. C.; Beutler, E.; Wong, C. H.; Balch, W. E.; Kelly, J. W. Chemical chaperones increase the cellular activity of N370S beta -glucosidase: a therapeutic strategy for Gaucher disease. Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 15428-15433.